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Blinded manuscript 
 
 
Expanding DBS indications: Remind the consequences of establishing a therapeutic practice 
 
Jared Pisapia and coauthors provide a sophisticated analysis of the ethical pitfalls of expanding Deep 
Brain Stimulation (DBS) as a therapeutic option for addiction and overeating associated with obesity. 
We agree with their expectation that DBS is a promising treatment for these conditions. However, 
the authors’ assessment of ethical issues of this research field lacks the long-term perspective of 
turning (successful) clinical trials into routine clinical practice.  
 
We propose to assess such long-term consequences along two dimensions: The first one is the 
patient-related dimension which involves, among others, information of patients, informed consent 
in normal treatment and research, shared decision-making, criteria for patient selection, the 
assessment of outcome parameters, the psychosocial impact of the treatment, and follow-up 
strategies. The second dimension is the infrastructure-related dimension which captures all aspects 
that are important for the development of a DBS infrastructure which can guarantee high-quality 
interventions. This includes issues like differences in technical and organizational procedures of 
centers, financing DBS interventions and research, long-term planning of center development, the 
information flow towards the public about chances and risks of DBS, and legislative issues of DBS 
(Abosch et al., 2012; Fins et al., 2012). 
 
We recently have performed two surveys among DBS experts (n=113) and DBS centers (n=135) on 
the global practice of DBS (Christen et al., in preparation) that indeed indicate, as Pisapia and 
coauthors mention, that the indication spectrum of DBS is rapidly expanding. This trend includes 
even diseases for which many DBS experts think that the success probability of DBS is low (e.g. 
Alzheimer’s disease). This trend is, according to many experts, driven also by commercial interests. 
Of the centers in our survey, 16.3% plan to implement DBS research on addiction and 12.6% on 
obesity within the next five years – i.e. it is indeed timely to start thinking on ethical consequences of 
this notably expansion. 
 
Some of our findings outline additional ethical aspects that need to be considered and that go 
beyond mere research ethics that is the primary focus of Pisapia and colleagues. First, in the patient-
related dimension, the information and the attitudes of the gate keepers to DBS, namely those 
physicians who are the key players with respect to patient information and patient referral, have to 
be considered. This is important since the portions of patients and family members with realistic 
expectations significantly correlate with a positive evaluation of DBS, and doubts as well as 
unrealistic expectations correlated with a negative attitude towards the operation (Südmeyer et al., 
2012). Furthermore, the communication of physicians with patients about medical interventions with 
a high degree of scientific uncertainty about their benefits and harms, is influenced both by 
individual differences in physicians’ tolerance of uncertainty as well as physicians’ beliefs about their 
patients' tolerance of uncertainty (Portnoy 2011). Therefore, these two aspects of uncertainty 
tolerance of the gate keepers are decisive for the quality of information and referral of patients. For 
Parkinsonian patients, we have found that the neurologists in private practice are the gate keepers to 
DBS. With respect to DBS in addiction and obesity, it has to be investigated who would and should be 
the gate keepers and how adequate patient information and patient referral can be guaranteed. We 
expect that the referral practice will differ because these two conditions have different gate keepers: 
Patients suffering from addiction usually have regular contacts with social workers who are 
traditionally critical with respect to biological disease models and biomedical interventions for 
changing behavior. But if they are treated by psychiatrists (particularly in university hospitals), they 
might find gate keepers who are interested in DBS research. In contrast, given the multiple causes of 
obesity, different medical specializations will become gate keepers for DBS. Furthermore, we expect 
that a few cases of successfully treated obese patients will cause a media hype which will raise 
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unrealistic expectations in people with quite different causes of obesity. This will lead to a patient-
driven demand for DBS. In summary, we expect that physicians, who will become gate keepers for 
DBS for the treatment of addiction or obesity, will be confronted with demands for which they 
normally lack competence.  
 
Second, we have found in our surveys that experts underestimate the frequency of some sequelae 
when compared with the literature. This does not necessarily indicate that the experts 
underestimate actual risks, as the expert opinions may reflect an improvement in practice that has 
not yet been included in reviews, which are usually based on outcome studies that reflect the state-
of-the art of some years ago. However, it could also hint to a “habituation effect” for established 
DBS-indications, which is further corroborated by the findings that one third of the centers involve 
only the core team (neurology and neurosurgery) and maximal one additional discipline (e.g., 
psychiatry, neuropsychology) in routine interventions, and that more than half of the centers use 
devise programming times that are lower than recent guidelines suggest. Such habituation effects 
may be inevitable, as they may also be related to efforts to reduce the costs of the intervention. But 
therefore one should analyze whether such habituation effects may also happen for novel patient 
groups and to what extent this may endanger the quality of the intervention. 
 
A third aspect refers to the infrastructure-related dimension and concerns the impact of novel DBS 
indications on the capacity of DBS centers. As Pisapia and colleagues point out, addiction and 
particularly obesity affect many people – raising the question, how many additional DBS patients had 
to be expected if DBS turned out to be effective in these conditions. Indeed, to estimate the future 
patient load for DBS centers is a difficult question even regarding only the established DBS conditions 
for several reasons: First the referral praxis of movement disorder specialists compared to other 
physicians  differs significantly in identifying appropriate candidates for established as well as for 
novel indications (Katz, 2011). Second, the referring physicians underestimate the number of suitable 
patients (Oyama et al., 2012). Third, women are under-represented in the patients referred (Setiavan 
et al., 2006); this might change in future. A reasonable guess is that 10-20 % of PD patients qualify for 
DBS (Christen & Müller, 2012) – but according to our research, countries like Canada, England, Italy 
and Japan may have insufficient capacities in order to deal already with the current patient load. As 
DBS is a high-tech intervention requiring considerable investment in material and manpower, an 
ethical evaluation of research on indications that have the potential to substantially increase the 
number of persons receiving DBS must take such issues into account. 
 
Finally, as Pisapia and colleagues note, manipulating the reward center may have long-term 
consequences for the ability to enjoy life and to pursue goals, and for the social embedding of 
patients. As known from movement disorders, DBS can have paradox effects, namely psychosocial 
problems in spite of a good clinical outcome (overview: Müller & Christen, 2011). Such problems may 
occur more frequently and in an aggravated manner when the reward system is targeted by DBS.  
 
Taking all these points together, the ethical assessment of the expansion of DBS indications requires 
additionally to the analysis of research ethical issues an analysis of foreseeable consequences when 
potentially successful clinical trials will turn into routine practice. 
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